| Objective: Endometrial cancer are the three major female genital malignant tumor of the epidemiological investigation and research that, in recent years, there is a marked increase in the incidence trend. At present, domestic and foreign researchers generally agreed that: the incidence of tumor development, invasion and metastasis is a common variety of factors involved in the complex process. This experiment by studying the endometrial carcinoma aromatase P450, adhesion molecule CD24 and c-erbB-2 protein expression to explore the aromatase P450, adhesion molecule CD24 and c-erbB-2 protein in endometrial carcinoma Expression and three on the occurrence and development of endometrial cancer and the role of the relationship among the three.Methods: Immunohistochemical SP method in 54 cases of endometrial cancer, including 50 cases of endometrial adenocarcinoma, endometrial papillary adenocarcinoma in 4 cases, and complex endometrial hyperplasia 13 cases, 12 cases of atypical hyperplasia in the aromatic enzyme P450, adhesion molecule CD24 and c-erbB-2 protein expression studies, as well as the normal proliferative endometrium in 15 cases as control group. x2 test using statistical methods, the use of statistical software SPSS11.5 of data for statistical analysis. Immunohistochemical SP method in 54 cases of endometrial cancer, including 50 cases of endometrial adenocarcinoma, endometrial papillary adenocarcinoma in 4 cases, and complex endometrial hyperplasia 13 cases, 12 cases of atypical hyper- plasia in the aromatic enzyme P450, adhesion molecule CD24 and c-erbB-2 protein expression studies, as well as the normal proliferative endometrium in 15 cases as control group. x2 test using statistical methods, the use of statistical software SPSS 11.5 of data for statistical analysis.Results: 1 Normal proliferative endometrial no expression of aromatase P450, the observation group in the P450 aromatase-positive expression, one of endometrial hyperplasia complex group positive expression rate of 46.1% (6/13), endo- metrial atypical hyperplasia group The positive expression rate was 66.7% (8/12), endometrial cancer group the positive exp- ression rate of 68.5% (37/54), the control group compared with the Observer Group have statistical significance (p <0.05), P450 aromatase in endometrial hyperplasia complex group of endo- metrial atypical hyperplasia and endometrial cancer group, posi- tive expression rate of comparison, the differences were not sta- tistically significant (p> 0.01). P450 aromatase in endometrial carcinoma without myometrial invasion group, superficial myo- metrial infiltration and deep myometrial group positive expre- ssion rates were 50% (5/10), 64% (9/25), 84.2% (3/19), among the three groups showed no statistically significant difference (p>0.05), showed that aromatase P450 expression level has nothing to do with the depth of myometrial invasion. P450 aro- mataseâ… at surgery during the clinical stage of the positive ex- pression rate of 62.5% (15/24), clinical stage at surgery periodâ…¡positive expression rate was 78.9% (15/19), in clinical surg- ery Phaseâ…¢-â…£during the positive expression rate of 63.6% (7/11), the positive rate among the three groups were compared there was no significant difference (p>0.05). Results showed that expression of P450 wasn't correlated with the differential degree (p>0.05).2 In the normal proliferative endometrium without adhe- sion molecule CD24 expression in endometrial hyperplasia complex group of positive expression rate of 53.8% (7/13), endometrial atypical hyperplasia group positive expression rate was 66.7% (8/12), endometrial cancer group the positive ex- pression rate of 72.2% (39/54), the control group compared with the Observer Group have statistical significance (p<0.05); ad- hesion molecule CD24 in endometrial carcinoma group, intra- uterine membrane atypical hyperplasia and complex hyperplasia group differences in positive expression rate of 22 compared no statistical significance (p>0.01). Adhesion molecule CD24â… at surgery during the clinical stage of the positive expression rate of 62.5% (15/24), clinical stage at surgery periodâ…¡positive expression rate was 78.9% (15/19), clinical stage at surgeryâ…¢-â…£during the positive expression rate of 81.8% (9/11), the posi- tive rate among the three groups were compared there was no significant difference (p>0.01). Results showed that expression of CD24 wasn't correlated with the differential degree (p>0.05). Adhesion molecule CD24 in endometrial carcinoma without myometrial invasion group, superficial myometrial infiltration and deep myometrial group positive rates were 30% (3/10), 76% (19/25), 84.2% (17/19), three inter-group difference was statisti- cally significant(p<0.05).3 c-erbB-2 protein in normal endometrial no expression, in endometrial hyperplasia complex group of positive expression rate of 38.5% (5/13), atypical hyperplasia group of positive expression rate of 41.7% (5/12) , endometrial cancer group the positive expression rate was 57% (30/54), the control group compared with the Observer Group have statistical significance (p<0.05). c-erbB-2 protein in surgery during the clinical stageâ… positive expression rate was 33.3% (8/24), clinical stage at surgeryâ…¡period of the positive expression rate of 68.4% (13/19), at surgery clinical stageâ…¢-â…£during the positive ex- pression rate of 81.8% (9/11) among the three groups to com- pare the difference has statistical significance (p <0.05). Results showed that expression of c-erbB-2 wasn't correlated with the differential degree (p>0.05). In endometrial carcinoma without myometrial invasion group, superficial myometrial infiltration and deep myometrial group positive rates were 40% (4/10), 44% (11/25), 78.9% (15/19) among the three groups was statistically significant difference (p<0.05). Conclusion: 1 P450 aromatase in endometrial carcinoma showed that high expression of P450 aromatase in endometrial cancer probably played a certain role, Prompted P450 aromata- se in endometrial cancer may be the clinical monitoring of the biological target.2 Adhesion molecule CD24 and c-erbB-2 pro- tein in endometrial cancer and high expression, suggesting that both in endometrial cancer invasion and metastasis play a cer- tain role, could serve as a prediction of endometrial cancer in- vasion and metastasis potential biological target.3 Aromatase P450, adhesion molecule CD24 and c-erbB-2 may be involved in endometrial cancer invasion and metastasis of a series of pathological and physiological processes.4 Research of aro- matase P450, in order to aromatase inhibitors in endometrial adenocarcinoma of the clinical application provides a theore- tical basis. |
PDF Full Text Request